Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217618 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2409021 in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02217618: Completed Phase 1 study of Healthy Participants, sponsored by Eli Lilly and Company.
NCT02217618 is a Phase 1 study of Healthy Participants that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02217618, a Phase 1 study of Healthy Participants, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.
Primary Outcome
Area under the concentration versus time curve from zero to infinity (AUC\[0-inf\]) of LY2409021 is presented.
Conditions Studied
Interventions
- DRUG LY2409021
Study Locations (1)
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT02217618 record still lists
NCT02217618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which LY2409021 is the first listed.
NCT02217618 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02217618 about?
NCT02217618 is a clinical study titled "A Study of LY2409021 in Healthy Participants". The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occu...
What is the current status of trial NCT02217618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2014-09.
What conditions does trial NCT02217618 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT02217618?
The interventions under investigation include: LY2409021 (DRUG).
Who is sponsoring clinical trial NCT02217618?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02217618 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02217618's enrollment target sits among peer trials
16 97th of 119 higher than 16 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia